Company Name: Trillium Therapeutics Inc.    

Trillium Therapeutics Inc. is a clinical stage immuno-oncology company. The company is engaged in the development of therapies designed to treat cancer. The company’s lead program is a fusion protein that is designed to block the activity of CD47 in cancer cells (preventing them from delivering a “don’t eat me” signal to macrophages).

Ticker Symbol: TRIL (NASDAQ)

Company Website:

Social Media: Trillium Therapeutics LinkedIn

Headquarters: Toronto, Ontario, Canada